Navigation Links
American Oriental Bioengineering Comments on Recent Property Purchase
Date:1/9/2009

NEW YORK, Jan. 9 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) ("AOBO" or "the Company"), a leading marketer, distributor and manufacturer of pharmaceutical and healthcare products in China, today commented on its recent purchase of buildings and land in the Beijing Economic-Technological Development Area (BDA) for approximately $70.0 million.

Mr. Tony Liu, Chairman and Chief Executive Officer of AOBO, stated, "Our recent property purchase in the BDA is a long-term investment in AOBO which builds out our multi-functional headquarters and centralizes our management in Beijing, while deepening our presence in a very important development region focused on attracting leading pharmaceutical companies. Additionally, at a time when our significant cash position yields negative real returns, this fixed asset allocation does not constrain our financial flexibility, but rather, we believe, positions us to secure government support in various forms, such as R&D grants related to the PRC's stimulus plan as well as potential low-interest bank loans."

Liu continued, "While we have not always elaborated on our motivations at the time, due to economic, competitive and other reasons, we consistently and effectively have navigated China's complex economic and competitive landscape, and have created significant shareholder value in the process. We believe this property purchase is no departure from AOBO's proven past."

"Our goal remains consistent. We continue to focus on becoming a top-five pharmaceutical company in China and we are aggressively yet prudently pursuing organic and acquisition-led growth. We emphasize that China's challenging economic environment and the uncertainty created by the upcoming healthcare reform necessitates that we remain flexible, influential a
'/>"/>

SOURCE American Oriental Bioengineering, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tips from the journals of the American Society for Microbiology
2. Elsevier Introduces The American Journal of Medicine Blog
3. The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database
4. Transgenomic Receives Accreditation From College of American Pathologists
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
7. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
8. 100% Non-Incision Cosmetic Surgery, The 'Frame Thread Lift,' Debuts December 14, 2008 At American Academy Of Anti-Aging Medicine In Las Vegas
9. BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition
10. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
11. Growing Interest in DNA-Based Genetic Testing Among African American with Historic Election of President Elect Barack Obama
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its ... Thursday, August 13, 2015, before the open of market.  ... a conference call to discuss the financial results and ... financial results and business update will be publicly distributed ... (US) or 1-412-542-4131 (international) and reference Pfenex to access ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead Levee Design Engineering Manager ... Orange County, Texas area from future storm surge flooding, such as occurred in Hurricane ... levee alignment alternatives for providing protection, Costello also balanced socio-economic and environmental needs ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2
... 2011 Auxilium Pharmaceuticals, Inc. (Nasdaq: ... financial results for the fourth quarter and the ... highlighted important commercial, regulatory and clinical development progress ... operational guidance for 2011. (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO) ...
... February 9, 2011 Engineers and scientists collaborating at ... demonstrated the world,s first programmable nanoprocessor. The groundbreaking ... in the journal Nature , represents a significant ... can be assembled from synthesized nanometer-scale components. It ...
... The New England Journal of Medicine (NEJM) ... plus best supportive care (BSC) more than doubled progression-free ... plus BSC in patients with advanced pancreatic neuroendocrine tumors ... (RAD001 In Advanced Neuroendocrine Tumors), were first presented last ...
Cached Biology Technology:Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 2Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 3Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 4Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 5Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 6Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 7Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 8Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 9Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 10Researchers at Harvard and MITRE produce world's first programmable nanoprocessor 2Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 2Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 3Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 4Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 5Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 6Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 7Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 8Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 9Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 10Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 11Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 12
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/7/2015)... June 30, 2015 ... the addition of the "Capacitive Fingerprint Sensors ... To this date, fingerprint sensing technology is ... fingerprint sensors are well developed. This patent landscape ... The domain of capacitive fingerprint sensors ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... focus on forestsas opposed to the entire landscapecould ... poor in developing countries, said a Nairobi-based agroforestry ... forest degradation is driven by forces outside forests, ... land uses that involve the whole landscape, not ...
... This release is available in French . ... Laval, in collaboration with Nova Scotia Agricultural College, have discovered ... to double the lifespan of Christmas trees in homes. The ... scientific journal Trees . The researchers have identified ...
... Personality is not just a feature unique to humans ... have revealed that also brown trout have individual characters ... the Department of Zoology at the University of Gothenburg ... trout from watercourses on the west coast of Sweden. ...
Cached Biology News:Towards an efficient, effective and equitable REDD+ 2Towards an efficient, effective and equitable REDD+ 3Towards an efficient, effective and equitable REDD+ 4Researchers discover a way to delay Christmas tree needle loss 2
Taq DNA polymerase, 10,000U...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
Request Info...
Biology Products: